Natural History of Obesity Subphenotypes: Dynamic Changes Over Two Decades and Prognosis in the Framingham Heart Study.
Adult
Atherosclerosis
/ epidemiology
Cross-Sectional Studies
Diabetes Mellitus, Type 2
/ epidemiology
Female
Follow-Up Studies
Humans
Hypertension
/ epidemiology
Male
Massachusetts
/ epidemiology
Metabolic Syndrome
/ complications
Middle Aged
Obesity
/ complications
Prevalence
Prognosis
Renal Insufficiency, Chronic
/ epidemiology
Risk Assessment
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
01 03 2019
01 03 2019
Historique:
received:
18
06
2018
accepted:
15
10
2018
pubmed:
20
10
2018
medline:
18
12
2019
entrez:
20
10
2018
Statut:
ppublish
Résumé
The natural histories of obesity subphenotypes are incompletely delineated. To investigate dynamic changes in obesity subphenotypes and associations with outcomes. Framingham Offspring Cohort participants (n = 4291) who attended the examination cycles 2 (1979 to 1983) to 7 (1998 to 2001), which included 26,508 participant observations. Obesity subphenotypes [metabolically healthy nonobese (MHNO), metabolically healthy obese (MHO), metabolically unhealthy nonobese (MUNO), and metabolically unhealthy obese (MUO)] were ascertained based on metabolic health (<2 Adult Treatment Panel III criteria). The outcomes were subclinical cardiovascular disease (CVD), incident diseases [diabetes, hypertension, chronic kidney disease (CKD), CVD], and all-cause mortality. At baseline, 4% and 31% of participants exhibited the MHO and MUNO subphenotypes, respectively. Four-year probability of MHO participants becoming MUO was 43% in women and 46% in men. Compared with MHNO, MHO participants had 1.28-fold (95% CI, 0.85 to 1.93) and 1.92-fold (95% CI, 1.38 to 2.68) higher odds of subclinical CVD and coronary artery calcification, respectively; corresponding values for MUNO were 1.95 (1.54 to 2.47) and 1.92 (1.38 to 2.68). During follow-up (median of 14 years), 231 participants developed diabetes, 784 hypertension, 423 CKD, 639 CVD, and 1296 died. Compared with MHNO, MHO conferred higher risks of diabetes [hazard ratio (HR), 4.69; 95% CI, 2.21 to 9.96] and hypertension (HR, 2.21; 95% CI, 1.66 to 2.94). Compared with MUO, MHO conferred lower risks of diabetes (0.21; 0.12 to 0.39), CVD (0.64; 0.43 to 0.95), and CKD (0.44; 0.27 to 0.73), but similar hypertension, cardiovascular mortality, and overall mortality risks. Over time, most MHO participants developed metabolic abnormalities and clinical disease. The MHO subphenotype is a harbinger of future risk.
Identifiants
pubmed: 30339231
pii: 5134201
doi: 10.1210/jc.2018-01321
pmc: PMC6349002
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
738-752Subventions
Organisme : NHLBI NIH HHS
ID : HHSN268201500001C
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL107385
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL125232
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201500001I
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL093328
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC25195
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL126136
Pays : United States
Références
N Engl J Med. 2017 Nov 30;377(22):2145-2153
pubmed: 29171811
Obesity (Silver Spring). 2012 Mar;20(3):651-9
pubmed: 21799477
J Am Coll Cardiol. 2015 Jan 6;65(1):101-102
pubmed: 25572516
Mayo Clin Proc. 2014 Mar;89(3):335-45
pubmed: 24582192
J Am Coll Cardiol. 2018 May 15;71(19):e127-e248
pubmed: 29146535
Eur Heart J. 2015 Mar 1;36(9):551-9
pubmed: 24670711
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
Int J Epidemiol. 2012 Jun;41(3):805-17
pubmed: 22467292
Ann Intern Med. 2017 May 2;166(9):628-636
pubmed: 28384781
Obesity (Silver Spring). 2014 Nov;22(11):2420-5
pubmed: 25131796
Diabetes Care. 2015 Nov;38(11):2177-87
pubmed: 26494809
Am J Epidemiol. 1979 Sep;110(3):281-90
pubmed: 474565
Diabetes Care. 2013 Aug;36(8):2294-300
pubmed: 23637352
Obesity (Silver Spring). 2008 Feb;16(2):463-9
pubmed: 18239660
JAMA. 2014 Feb 5;311(5):507-20
pubmed: 24352797
Circulation. 2010 Jan 19;121(2):230-6
pubmed: 20038741
Ann Intern Med. 2016 Mar 1;164(5):305-12
pubmed: 26857595
Int J Obes (Lond). 2017 Jan;41(1):170-177
pubmed: 27748744
JAMA Intern Med. 2014 Jan;174(1):15-22
pubmed: 24217719
Diabetes Care. 2009 Dec;32(12):2297-9
pubmed: 19729521
Int J Obes (Lond). 2015 Mar;39(3):514-9
pubmed: 25287753
Eur J Endocrinol. 2015 Nov;173(5):703-8
pubmed: 26286585
J Am Coll Cardiol. 2014 Jun 24;63(24):2679-86
pubmed: 24794119
JAMA. 2016 Jun 7;315(21):2284-91
pubmed: 27272580
Stat Med. 1988 Jan-Feb;7(1-2):205-22
pubmed: 3353604
Lancet Diabetes Endocrinol. 2013 Oct;1(2):152-62
pubmed: 24622321
Eur Heart J. 2013 Feb;34(5):389-97
pubmed: 22947612
Obes Rev. 2014 Sep;15(9):697-708
pubmed: 25059108
Eur J Prev Cardiol. 2016 Jun;23(9):956-66
pubmed: 26701871
J Am Soc Nephrol. 2002 Apr;13(4):1034-9
pubmed: 11912263
Int J Obes (Lond). 2011 Jul;35(7):971-81
pubmed: 20975726
Diabetes. 2007 Jun;56(6):1718-26
pubmed: 17369522
Ann Intern Med. 2013 Dec 3;159(11):758-69
pubmed: 24297192
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
J Am Coll Cardiol. 2017 Sep 19;70(12):1429-1437
pubmed: 28911506
Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27
pubmed: 29222373
J Clin Endocrinol Metab. 2012 Jul;97(7):2482-8
pubmed: 22508708
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
Am J Cardiol. 2008 Nov 1;102(9):1136-41, 1141.e1
pubmed: 18940279
J Clin Invest. 1997 Sep 1;100(5):1166-73
pubmed: 9303923
Eur Heart J. 2018 Feb 1;39(5):397-406
pubmed: 29020414